Ferritin as prognostic marker in multiple myeloma patients undergoing autologous transplantation

References

• Kalousova M, Krechler T, Jachymova M, et al. Ferritin as an independent mortality predictor in patients with pancreas cancer. Results of a pilot study. Tumour Biol 2012;33:1695–1700.
   PubMed Web of Science ®Google Scholar
• Cangemi G, Reggiardo G, Barco S, et al. Prognostic value of ferritin, neuron-specific enolase, lactate dehydrogenase, and urinary and plasmatic catecholamine metabolites in children with neuroblastoma. Onco Targets Ther 2012;5:417–423.
   PubMed Web of Science ®Google Scholar
• Alkhateeb AA, Han B, Connor JR. Ferritin stimulates breast cancer cells through an iron-independent mechanism and is localized within tumor-associated macrophages. Breast Cancer Res Treat 2013;137:733–744.
   PubMed Web of Science ®Google Scholar
• Linkesch W, Ludwig H. Serum ferritin and beta 2-microglobulin in patients with multiple myeloma. Cancer Detect Prev 1983;6:297–301.
   PubMedGoogle Scholar
• Papadaki H, Kyriakou D, Foudoulakis A, et al. Serum levels of soluble IL-6 receptor in multiple myeloma as indicator of disease activity. Acta Haematol 1997;97:191–195.
   PubMed Web of Science ®Google Scholar
• Patel AR, Shah PC, Vohra RM, et al. Serum ferritin levels in hematologic malignant neoplasms. Arch Pathol Lab Med 1980;104:509–512.
   PubMed Web of Science ®Google Scholar
• Kikuchi S, Kobune M, Iyama S, et al. Prognostic significance of serum ferritin level at diagnosis in myelodysplastic syndrome. Int J Hematol 2012;95:527–534.
   PubMed Web of Science ®Google Scholar
• Armand P, Kim HT, Cutler CS, et al. Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation. Blood 2007;109:4586–4588.
   PubMed Web of Science ®Google Scholar
• Mahindra A, Bolwell B, Sobecks R, et al. Elevated ferritin is associated with relapse after autologous hematopoietic stem cell transplantation for lymphoma. Biol Blood Marrow Transplantation 2008;14:1239–1244.
   PubMed Web of Science ®Google Scholar
• Song MK, Chung JS, Seol YM, et al. Elevation of serum ferritin is associated with the outcome of patients with newly diagnosed multiple myeloma. Korean J Intern Med 2009;24:368–373.
   PubMedGoogle Scholar
• Ludwig H, Linkesch W, Kasparu H, et al. Prospective, randomized comparison between double transplantation (T) with melphalan (200 mg/m2) and triple T with intermediate dose melphalan (100 mg/m2) in patients with multiple myeloma (an interim analysis). Blood 2006;108(Suppl. 1): Abstract 3083.
   Google Scholar
• Inoue S, Kawanishi S. Hydroxyl radical production and human DNA damage induced by ferric nitrilotriacetate and hydrogen peroxide. Cancer Res. 1987;47:6522–6527.
   PubMed Web of Science ®Google Scholar
• Dizdaroglu M, Rao G, Halliwell B, et al. Damage to the DNA bases in mammalian chromatin by hydrogen peroxide in the presence of ferric and cupric ions. Arch Biochem Biophys 1991;285:317–324.
   PubMed Web of Science ®Google Scholar
• Dizdaroglu M, Jaruga P. Mechanisms of free radical-induced damage to DNA. Free Radic Res 2012;46:382–419.
   PubMed Web of Science ®Google Scholar
• Stevens RG, Graubard BI, Micozzi MS, et al. Moderate elevation of body iron level and increased risk of cancer occurrence and death. Int J Cancer 1994;56:364–369.
   PubMed Web of Science ®Google Scholar
• Stevens RG, Jones DY, Micozzi MS, et al. Body iron stores and the risk of cancer. N Engl J Med 1988;319:1047–1052.
   PubMed Web of Science ®Google Scholar
• van Asperen IA, Feskens EJ, Bowles CH, et al. Body iron stores and mortality due to cancer and ischaemic heart disease: a 17-year follow-up study of elderly men and women. Int J Epidemiol 1995;24:665–670.
   PubMed Web of Science ®Google Scholar
• Knekt P, Reunanen A, Takkunen H, et al. Body iron stores and risk of cancer. Int J Cancer 1994;56:379–382.
   PubMed Web of Science ®Google Scholar
• Wu T, Sempos CT, Freudenheim JL, et al. Serum iron, copper and zinc concentrations and risk of cancer mortality in US adults. Ann Epidemiol 2004;14:195–201.
   PubMed Web of Science ®Google Scholar
• Nelson RL. Iron and colorectal cancer risk: human studies. Nutr Rev 2001;59:140–148.
   PubMed Web of Science ®Google Scholar
• Bradbear RA, Bain C, Siskind V, et al. Cohort study of internal malignancy in genetic hemochromatosis and other chronic nonalcoholic liver diseases. J Natl Cancer Inst 1985;75:81–84.
   PubMed Web of Science ®Google Scholar
• Elmberg M, Hultcrantz R, Ekbom A, et al. Cancer risk in patients with hereditary hemochromatosis and in their first-degree relatives. Gastroenterology 2003;125:1733–1741.
   PubMed Web of Science ®Google Scholar
• Niederau C, Fischer R, Sonnenberg A, et al. Survival and causes of death in cirrhotic and in noncirrhotic patients with primary hemochromatosis. N Engl J Med 1985;313:1256–1262.
   PubMed Web of Science ®Google Scholar
• Hsing AW, McLaughlin JK, Olsen JH, et al. Cancer risk following primary hemochromatosis: a population-based cohort study in Denmark. Int J Cancer 1995;60:160–162.
   PubMed Web of Science ®Google Scholar
• Osborne NJ, Gurrin LC, Allen KJ, et al. HFE C282Y homozygotes are at increased risk of breast and colorectal cancer. Hepatology 2010;51:1311–1318.
   PubMed Web of Science ®Google Scholar
• Edgren G, Reilly M, Hjalgrim H, et al. Donation frequency, iron loss, and risk of cancer among blood donors. J Natl Cancer Inst 2008;100:572–579.
   PubMed Web of Science ®Google Scholar
• Torti SV, Torti FM. Iron and cancer: more ore to be mined. Nat Rev Cancer 2013;13:342–355.
   PubMed Web of Science ®Google Scholar
• Miller LD, Coffman LG, Chou JW, et al. An iron regulatory gene signature predicts outcome in breast cancer. Cancer Res 2011;71: 6728–6737.
   PubMed Web of Science ®Google Scholar
• Cozzi A, Corsi B, Levi S, et al. Analysis of the biologic functions of H- and L-ferritins in HeLa cells by transfection with siRNAs and cDNAs: evidence for a proliferative role of L-ferritin. Blood 2004; 103:2377–2383.
   PubMed Web of Science ®Google Scholar
• Coffman LG, Parsonage D, D’Agostino R Jr, et al. Regulatory effects of ferritin on angiogenesis. Proc Natl Acad Sci USA 2009;106: 570–575.
   PubMed Web of Science ®Google Scholar
• Pham CG, Bubici C, Zazzeroni F, et al. Ferritin heavy chain upregulation by NF-kappaB inhibits TNFalpha-induced apoptosis by suppressing reactive oxygen species. Cell 2004;119:529–542.
   PubMed Web of Science ®Google Scholar
• Chesi M, Bergsagel PL. Molecular pathogenesis of multiple myeloma: basic and clinical updates. Int J Hematol 2013;97:313–323.
   PubMed Web of Science ®Google Scholar
• Campanella A, Santambrogio P, Fontana F, et al. Iron increases the susceptibility of multiple myeloma cells to bortezomib. Haematologica 2013;98:971–979.
   PubMed Web of Science ®Google Scholar